The Global CAR T Cell Therapy Market is expected to register a CAGR of 58.52% during the forecast period, with a market value of USD 346.75 Million in 2018. Global CAR T Cell Therapy Market: Information by Target Antigen (CD19, CD22 and others), Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma and others) and Region – Forecast till 2025
Chimeric Antigen Receptor (CAR) T Cell Therapy is an immunotherapy used for cancer treatment. In this therapy, T cells from patient body are isolated and inserted in the CAR gene so that the gene for the specific receptor binds to a certain protein on the patient’s cancer cells.
Growing prevalence of cancer across the world, technological advancement for advanced & reliable treatment for cancer, and rise in the number of cell therapy clinical studies are driving the growth of the global CAR T Cell Therapy market. According to the National Cancer Institute, it is estimated that 1,735,350 new cases of cancer were diagnosed, and 609,640 deaths were reported in the US in 2018. Moreover, the growing pharmaceutical industry is also expected to boost market growth.
Get Exclusive Sample Copy of “CAR-T Cell Therapy Market” Report @ https://www.marketresearchfuture.com/sample_request/8102
Key Findings of the Study
- The Global CAR T cell Therapy Market is projected to reach USD 8716.06 Million by 2025 at a CAGR of 58.52% during the review period from 2019 to 2025.
- The US accounted for the largest share of the global market due to the rising prevalence of cancer in the country.
- The CD19 target antigen accounted for the largest target antigen segment, with a revenue of USD 56 million in 2018.
Key Players – CAR-T Cell Therapy Market
Market Research Future (MRFR) recognizes the following companies as the key players in CAR T Cell Therapy Market: There are plenty of large and small market players which operate in this market all over the globe.
Market Research Future (MRFR) recognizes the following companies as key players in the global CAR T Cell therapy market that include
- Novartis AG (Switzerland),
- Pfizer, Inc. (US),
- Kite Pharma (US),
- Cellectis (France),
- Autolus Therapeutics PLC (UK),
- CARsgen Therapeutics (China),
- Juno Therapeutics (US),
- Sorrento Therapeutics (US),
- Legend Biotech (US),
- Mustang Bio (US),
Some of the key strategies followed by players operating in the global CAR T cell therapy market were innovation, product development, and acquisitions & mergers.
In April 2019, Autolus Therapeutics PLC was granted with an orphan drug designation, to autologous enriched T-cells, genetically modified with a retroviral vector to express two chimeric antigen receptors targeting CD19 and CD22 (AUTO3) for the treatment of acute lymphoblastic leukemia (ALL), by the US FDA.
In April 2019, Cellectis received approval from the US FDA to initiate a Phase 1 clinical trial for UCARTCS1, in patients with multiple myeloma (MM).
In May 2018, Kite Pharma leased a new facility in the Netherlands to engineer cell therapies in Europe. With this, the company aims to strengthen its position in the global CAR T cell therapy market.
Segments – CAR-T Cell Therapy Market
The global CAR T cell therapy market, by target antigen, has been segmented into CD19, CD22, and others. The CD19 target antigen segment accounted for a value of USD 342.56 million in 2018. On the basis of application, the global CAR T cell therapy market is segmented into acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and others.
Regional Analysis – CAR-T Cell Therapy Market
The global CAR T cell therapy market, based on region, is divided into the US, Europe, China, and the rest of the world.
The US is expected to hold the largest share of the global CAR T cell therapy market. This is owing to the increasing cases of cancer in the country. Europe showed a considerable amount of growth in the market due to an increase in the occurrences of hematologic cancer such as leukemia, lymphoma, and multiple myeloma. Europe held a market share of 9.15% in the global CAR T cell therapy market. China is estimated to significantly grow in the global market due to the developing healthcare infrastructure and increasing disposable income. Also, the market in the Middle East & Africa is expected to show the least growth owing to limited healthcare access and affordability among the population.
Some Brief Table of Contents of Report
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porters Five Forces Analysis
5.1.1 Bargaining Power Of Suppliers
TOC Continued…
Do You Have Specific Requirement? Ask To Our Experts https://www.marketresearchfuture.com/enquiry/8102
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Statistical Report, Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Hadapsar, Pune – 411028
Maharashtra, India
Phone: +1 646 845 9312